Baltic Atherosclerosis Society Congress 2018 Tallinn

Event Programme

Friday, 06 April


08:00-08:45Registration Open / Arrival Tea and Coffee
08:45-09:15OPENING OF THE CONGRESS
Chair: Alberico Catapano (IT), Gustavs Latkovskis (LV), Béla Merkely (HU),
Margus Viigimaa (EE)

Welcome speech by Mr. Jüri Ratas, Prime Minister of Republic of Estonia
09:15-10:45PLENARY SESSION I
Lipid management in secondary prevention of cardiovascular disease
Baltic Atherosclerosis Society – European Atherosclerosis Society joint session

Chair: Maciej Banach (PL), Alberico Catapano (IT), Margus Viigimaa (EE)
  • Lipid-lowering therapy: present and future developments. Keynote lecture. Alberico Catapano (IT)
  • Novel pathways of atherogenesis and challenging therapeutic targets. Rimvydas Slapikas (LT)
  • Statin intolerance definition, diagnosis and management in 2018. Maciej Banach (PL)
  • Current development of lipid management in Baltic countries. Margus Viigimaa (EE)
10:45-11:15Coffee break, Press conference
11:15-12:30PLENARY SESSION II
Cardiovascular Risk in Diabetes

Chair: Peter Nilsson (SE), Lars Rydén (SE), Vallo Volke (EE)
  • Cardiovascular outcome trials in type 2 diabetes. Lessons learned from the perspective of a cardiologist. Keynote lecture. Lars Rydén (SE)
  • Antidiabetic drugs and cardiovascular risk – endocrinologist’s point of view. Vallo Volke (EE)
  • Cardiovascular risk management in diabetes and hypertension. Peter Nilsson (SE)
12:30-13:30Lunch
13:30-15:10Satellite Symposia
13:30-14:15AMGEN
Integrating anti-PCSK9 therapy into secondary prevention of CVD

Chair: Chair: Margus Viigimaa (EE), Gustavs Latkovskis (LV)
  • Role of PCSK9 inhibition in secondary prevention.Alberico Catapano (IT)
  • FOURIER: PCSK9 inhibition decreases CV events in high-risk patients. Terje Pedersen (NO)
  • Effectiveness and safety of very low LDL-c values with evolocumab: lowest is best. Alberico Catapano (IT)
  • Which patients could benefit from treatment in clinical practice? Alberico Catapano (IT)
14:20-15:05Berlin-Chemie Menarini
Chair: Chair: Margus Viigimaa (EE)
Invitation to Berlin-Chemie Menarini Satellite Symposia in PDF-format.
  • The newest guidelines on hypertension: focus on tight blood pressure control. Margus Viigimaa (EE)
  • Uncontrolled hypertension – time to act. Lessons learned from case studies. Kārlis Trušinskis (LV)
  • Discussion
15:10-16:40PLENARY SESSION III
Atherosclerosis and heart
Baltic Atherosclerosis Society – European Society of Cardiology joint session

Chair: Béla Merkely (HU), Aleksandras Laucevicius (LT), Terje Pedersen (NO)
  • Lipid-lowering therapy in the future: Will statins still be the basis? Terje Pedersen (NO)
  • Prevention of sudden cardiac death - the role of implantable devices. Béla Merkely (HU)
  • Is metabolic syndrome high or moderate cardiovascular (cardiometabolic) risk entity: results of Lithuanian High Cardiovascular Risk (LitHiR) programme. Aleksandras Laucevicius (LT)
  • How to improve BP Control? Novel Initiatives. Serap Erdine (TR)
  • Discussion
16:40-17:00Coffee break
17:00-18:40Satellite Symposia
17:00-17:45Boehringer Ingelheim
Anticoagulation Management In Special Situations- Innovative or Conservative Treatment?
Invitation to Boehringer Ingelheim Satellite Symposia in PDF-format.
  • Rewire your thinking on AF ablation. Kārlis Trusinskis (LV)
  • Improving care decisions after coronary revascularization. Elena Baranova (RUS)
17:50-18:35AstraZeneca
Treat to success or treat to failure. What does real life tell us about Type 2 DM?
Invitation to AstraZeneca Satellite Symposia in PDF-format.
Chair: Kārlis Trusinskis (LV), Kristīne Ducena (LV)
18:40-19:50PARALLEL SESSION I
Familial hypercholesterolemia

Chair: Gustavs Latkovskis (LV), Michal Vrablik (CZ)
  • Three-year experience of the Latvian Registry of Familial Hypercholesterolemia: challenges and achievements. Gustavs Latkovskis (LV)
  • Familial hypercholesterolemia screening: International and national initiatives.
    Žaneta Petrulionienė (LT)
  • FH management: expectations and reality. Michal Vrablik (CZ)
  • Discussion: Familial Hypercholesterolemia registries in Europe and in Baltic countries
18:40-19:50PARALLEL SESSION II
Coronary atherosclerosis: physiology and management

Chair: Sergei Nazarenko (EE), Kārlis Trušinskis (LV)
  • Vascular restoration therapy: the role of intravascular imaging guided plaque modification prior drug eluting stent or bioresorbable scaffold implantation. Andrejs Ērglis (LV)
  • Vascular Protection by Factor Xa Inhibition in Patients with Coronary and/or Peripheral Artery Disease. Kārlis Trusinskis (LV)
  • Role of 18F-FDG-PET/CT in Management of Atherosclerotic Plaque: Current Evidence. Sergei Nazarenko (EE)
20:00-22:00Welcome reception at Valuutabaar (Hard Currency Bar), Congress Venue

Saturday, 07 April


09:00-10:00PLENARY SESSION IV
Cardiovascular risk factors and management

Chair: Irina Chazova (RU), Iveta Mintāle (LV)
  • Impact of chronic stress on atherosclerosis process. Dovile Karciauskaite (LT)
  • Arterial hypertension and atherosclerosis: data from Russian national registry. Irina Chazova (RU)
  • Lifestyle management in cardiovascular prevention. Iveta Mintāle (LV)
10:00-11:20PLENARY SESSION V
Goals in blood pressure, lipids and glucose. Are we treating well?

Chair: Serap Erdine (TR), Andrejs Ērglis (LV), Rimvydas Slapikas (LT)
  • Goals in blood pressure. Peter Nilsson (SE)
  • Goals in lipids. Gustavs Latkovskis (LV)
  • Goals in glucose. Mart Roosimaa (EE)
11:00-11:20Coffee break
11:20-11:50PLENARY SESSION VI
History of the Baltic Society of Atherosclerosis. General Assembly

Chair: Zita Kučinskienė (LT), Gustavs Latkovskis (LV), Margus Viigimaa (EE)
11:50-12:50PLENARY SESSION VII
Personalised diagnostics and treatment of atherosclerotic disease

Chair: Valdis Pīrāgs (LV), Peeter Ross (EE)
  • From Biobanking to Precision Medicine and beyond: the Estonian Experience. Andres Metspalu (EE)
  • Using the principles of stratified medicine to individualize treatment strategies for diabetic patients. Experience from the Latvian Genome Data Base. Valdis Pīrāgs (LV)
  • Importance of data quality in nation-wide e-health system for personalized medicine decision support applications. Peeter Ross (EE)
12:50-13:00Closing remarks
13:00Say Goodbye Coffee



Last update 04.04.2018 20:49